PDB Short entry for 4Q1R HEADER SUGAR BINDING PROTEIN 04-APR-14 4Q1R TITLE GALECTIN-1 IN COMPLEX WITH LIGAND AN027 COMPND MOL_ID: 1; COMPND 2 MOLECULE: GALECTIN-1; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: GAL-1, 14 KDA LAMININ-BINDING PROTEIN, HLBP14, 14 KDA COMPND 5 LECTIN, BETA-GALACTOSIDE-BINDING LECTIN L-14-I, GALAPTIN, HBL, HPL, COMPND 6 LACTOSE-BINDING LECTIN 1, LECTIN GALACTOSIDE-BINDING SOLUBLE 1, COMPND 7 PUTATIVE MAPK-ACTIVATING PROTEIN PM12, S-LAC LECTIN 1; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: LGALS1; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS RATIONAL DRUG DESIGN, SUGAR BINDING PROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR C.GRIMM,N.BERTLEFF-ZIESCHANG REVDAT 1 07-OCT-15 4Q1R 0 JRNL AUTH C.GRIMM,N.BERTLEFF-ZIESCHANG JRNL TITL GALECTIN-1 IN COMPLEX WITH LIGAND AN027 JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. 1.47 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (PHENIX.REFINE: 1.8.2_1309) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE- REMARK 3 : KUNSTLEVE,LI-WEI HUNG,ROBERT IMMORMINO, REMARK 3 : TOM IOERGER,AIRLIE MCCOY,ERIK MCKEE,NIGEL REMARK 3 : MORIARTY,REETAL PAI,RANDY READ,JANE REMARK 3 : RICHARDSON,DAVID RICHARDSON,TOD ROMO,JIM REMARK 3 : SACCHETTINI,NICHOLAS SAUTER,JACOB SMITH, REMARK 3 : LAURENT STORONI,TOM TERWILLIGER,PETER REMARK 3 : ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.47 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 51.71 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.350 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.3 REMARK 3 NUMBER OF REFLECTIONS : 48324 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.156 REMARK 3 R VALUE (WORKING SET) : 0.154 REMARK 3 FREE R VALUE : 0.194 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.140 REMARK 3 FREE R VALUE TEST SET COUNT : 2000 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 51.7393 - 3.5425 0.99 3513 152 0.1608 0.1654 REMARK 3 2 3.5425 - 2.8118 0.99 3363 145 0.1529 0.1919 REMARK 3 3 2.8118 - 2.4564 1.00 3361 145 0.1486 0.1877 REMARK 3 4 2.4564 - 2.2318 0.99 3319 143 0.1349 0.1958 REMARK 3 5 2.2318 - 2.0718 1.00 3287 143 0.1272 0.1787 REMARK 3 6 2.0718 - 1.9497 1.00 3322 143 0.1265 0.1671 REMARK 3 7 1.9497 - 1.8520 0.99 3300 142 0.1351 0.1940 REMARK 3 8 1.8520 - 1.7714 0.99 3244 140 0.1550 0.2248 REMARK 3 9 1.7714 - 1.7032 1.00 3308 143 0.1710 0.2164 REMARK 3 10 1.7032 - 1.6444 1.00 3299 142 0.1773 0.2633 REMARK 3 11 1.6444 - 1.5930 0.99 3256 141 0.1779 0.2611 REMARK 3 12 1.5930 - 1.5475 0.98 3224 140 0.1955 0.2738 REMARK 3 13 1.5475 - 1.5067 0.99 3250 140 0.2204 0.2674 REMARK 3 14 1.5067 - 1.4700 0.99 3278 141 0.2658 0.3321 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.20 REMARK 3 SHRINKAGE RADIUS : 1.00 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.170 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 22.400 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.011 2374 REMARK 3 ANGLE : 1.546 3246 REMARK 3 CHIRALITY : 0.078 355 REMARK 3 PLANARITY : 0.007 435 REMARK 3 DIHEDRAL : 18.623 899 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4Q1R COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 09-APR-14. REMARK 100 THE RCSB ID CODE IS RCSB085495. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID23-1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9764 REMARK 200 MONOCHROMATOR : SI(111) REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M-F REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XDS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 48330 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.470 REMARK 200 RESOLUTION RANGE LOW (A) : 51.707 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.3 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.04700 REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 15.8000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.47 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 47.25 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.33 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: AMMONIUM SULFATE, PH 7.5, VAPOR REMARK 280 DIFFUSION, HANGING DROP, TEMPERATURE 289K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 21.57000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 55.58500 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 29.20500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 55.58500 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 21.57000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 29.20500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A -1 REMARK 465 MET A 0 REMARK 465 ALA A 1 REMARK 465 GLY B -1 REMARK 465 MET B 0 REMARK 465 ALA B 1 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 C LYS B 129 H CME B 130 1.37 REMARK 500 C LYS A 129 H CME A 130 1.38 REMARK 500 HD1 HIS B 52 O HOH B 373 1.50 REMARK 500 HH TYR A 104 O HOH A 333 1.54 REMARK 500 O HOH A 379 O HOH A 380 2.00 REMARK 500 OD1 ASP A 123 O HOH A 391 2.03 REMARK 500 O HOH B 391 O HOH B 395 2.05 REMARK 500 O HOH B 345 O HOH B 393 2.13 REMARK 500 O HOH B 348 O HOH B 352 2.15 REMARK 500 O HOH B 313 O HOH B 347 2.16 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 HH12 ARG A 20 OD2 ASP A 26 4555 1.19 REMARK 500 O HOH A 396 O HOH B 392 1565 2.00 REMARK 500 NH1 ARG A 20 OD2 ASP A 26 4555 2.04 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 VAL A 76 CB VAL A 76 CG2 -0.138 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 20 NE - CZ - NH1 ANGL. DEV. = -3.2 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PHE A 77 84.19 -152.94 REMARK 500 PRO A 78 46.56 -89.90 REMARK 500 PRO B 78 49.76 -91.18 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 PRO B 25 ASP B 26 -146.37 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 2XU A 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 2XU B 202 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 4Q1P RELATED DB: PDB REMARK 900 RELATED ID: 4Q26 RELATED DB: PDB REMARK 900 RELATED ID: 4Q27 RELATED DB: PDB REMARK 900 RELATED ID: 4Q2F RELATED DB: PDB DBREF 4Q1R A 0 134 UNP P09382 LEG1_HUMAN 1 135 DBREF 4Q1R B 0 134 UNP P09382 LEG1_HUMAN 1 135 SEQADV 4Q1R GLY A -1 UNP P09382 EXPRESSION TAG SEQADV 4Q1R GLY B -1 UNP P09382 EXPRESSION TAG SEQRES 1 A 136 GLY MET ALA CYS GLY LEU VAL ALA SER ASN LEU ASN LEU SEQRES 2 A 136 LYS PRO GLY GLU CME LEU ARG VAL ARG GLY GLU VAL ALA SEQRES 3 A 136 PRO ASP ALA LYS SER PHE VAL LEU ASN LEU GLY LYS ASP SEQRES 4 A 136 SER ASN ASN LEU CYS LEU HIS PHE ASN PRO ARG PHE ASN SEQRES 5 A 136 ALA HIS GLY ASP ALA ASN THR ILE VAL CYS ASN SER LYS SEQRES 6 A 136 ASP GLY GLY ALA TRP GLY THR GLU GLN ARG GLU ALA VAL SEQRES 7 A 136 PHE PRO PHE GLN PRO GLY SER VAL ALA GLU VAL CME ILE SEQRES 8 A 136 THR PHE ASP GLN ALA ASN LEU THR VAL LYS LEU PRO ASP SEQRES 9 A 136 GLY TYR GLU PHE LYS PHE PRO ASN ARG LEU ASN LEU GLU SEQRES 10 A 136 ALA ILE ASN TYR MET ALA ALA ASP GLY ASP PHE LYS ILE SEQRES 11 A 136 LYS CME VAL ALA PHE ASP SEQRES 1 B 136 GLY MET ALA CYS GLY LEU VAL ALA SER ASN LEU ASN LEU SEQRES 2 B 136 LYS PRO GLY GLU CME LEU ARG VAL ARG GLY GLU VAL ALA SEQRES 3 B 136 PRO ASP ALA LYS SER PHE VAL LEU ASN LEU GLY LYS ASP SEQRES 4 B 136 SER ASN ASN LEU CYS LEU HIS PHE ASN PRO ARG PHE ASN SEQRES 5 B 136 ALA HIS GLY ASP ALA ASN THR ILE VAL CYS ASN SER LYS SEQRES 6 B 136 ASP GLY GLY ALA TRP GLY THR GLU GLN ARG GLU ALA VAL SEQRES 7 B 136 PHE PRO PHE GLN PRO GLY SER VAL ALA GLU VAL CME ILE SEQRES 8 B 136 THR PHE ASP GLN ALA ASN LEU THR VAL LYS LEU PRO ASP SEQRES 9 B 136 GLY TYR GLU PHE LYS PHE PRO ASN ARG LEU ASN LEU GLU SEQRES 10 B 136 ALA ILE ASN TYR MET ALA ALA ASP GLY ASP PHE LYS ILE SEQRES 11 B 136 LYS CME VAL ALA PHE ASP MODRES 4Q1R CME A 16 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 4Q1R CME A 88 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 4Q1R CME A 130 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 4Q1R CME B 16 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 4Q1R CME B 88 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 4Q1R CME B 130 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE HET CME A 16 19 HET CME A 88 19 HET CME A 130 19 HET CME B 16 19 HET CME B 88 19 HET CME B 130 19 HET 2XU A 201 45 HET SO4 B 201 5 HET 2XU B 202 45 HETNAM CME S,S-(2-HYDROXYETHYL)THIOCYSTEINE HETNAM 2XU PROPYL 2-(ACETYLAMINO)-2-DEOXY-4-O-[3-O-({1-[2-(3- HETNAM 2 2XU HYDROXYPHENYL)-2-OXOETHYL]-1H-1,2,3-TRIAZOL-4- HETNAM 3 2XU YL}METHYL)-BETA-D-GALACTOPYRANOSYL]-BETA-D- HETNAM 4 2XU GLUCOPYRANOSIDE HETNAM SO4 SULFATE ION FORMUL 1 CME 6(C5 H11 N O3 S2) FORMUL 3 2XU 2(C28 H40 N4 O13) FORMUL 4 SO4 O4 S 2- FORMUL 6 HOH *206(H2 O) HELIX 1 1 PRO A 101 GLY A 103 5 3 HELIX 2 2 PRO B 101 GLY B 103 5 3 SHEET 1 A12 ALA A 67 TRP A 68 0 SHEET 2 A12 ASP A 54 ASP A 64 -1 N ASP A 64 O ALA A 67 SHEET 3 A12 ASN A 40 ALA A 51 -1 N ARG A 48 O THR A 57 SHEET 4 A12 PHE A 30 ASP A 37 -1 N LEU A 32 O PHE A 45 SHEET 5 A12 ILE A 117 GLY A 124 -1 O ALA A 121 N ASN A 33 SHEET 6 A12 VAL A 5 LEU A 11 -1 N ALA A 6 O MET A 120 SHEET 7 A12 VAL B 5 LEU B 11 -1 O VAL B 5 N SER A 7 SHEET 8 A12 ILE B 117 GLY B 124 -1 O MET B 120 N ALA B 6 SHEET 9 A12 PHE B 30 ASP B 37 -1 N ASN B 33 O ALA B 121 SHEET 10 A12 ASN B 40 ALA B 51 -1 O PHE B 45 N LEU B 32 SHEET 11 A12 ASP B 54 ASP B 64 -1 O THR B 57 N ARG B 48 SHEET 12 A12 ALA B 67 TRP B 68 -1 O ALA B 67 N ASP B 64 SHEET 1 B12 GLN A 72 ARG A 73 0 SHEET 2 B12 ASP A 54 ASP A 64 -1 N CYS A 60 O GLN A 72 SHEET 3 B12 ASN A 40 ALA A 51 -1 N ARG A 48 O THR A 57 SHEET 4 B12 PHE A 30 ASP A 37 -1 N LEU A 32 O PHE A 45 SHEET 5 B12 ILE A 117 GLY A 124 -1 O ALA A 121 N ASN A 33 SHEET 6 B12 VAL A 5 LEU A 11 -1 N ALA A 6 O MET A 120 SHEET 7 B12 VAL B 5 LEU B 11 -1 O VAL B 5 N SER A 7 SHEET 8 B12 ILE B 117 GLY B 124 -1 O MET B 120 N ALA B 6 SHEET 9 B12 PHE B 30 ASP B 37 -1 N ASN B 33 O ALA B 121 SHEET 10 B12 ASN B 40 ALA B 51 -1 O PHE B 45 N LEU B 32 SHEET 11 B12 ASP B 54 ASP B 64 -1 O THR B 57 N ARG B 48 SHEET 12 B12 GLN B 72 ARG B 73 -1 O GLN B 72 N CYS B 60 SHEET 1 C10 GLU A 105 PRO A 109 0 SHEET 2 C10 ASN A 95 LYS A 99 -1 N LEU A 96 O PHE A 108 SHEET 3 C10 SER A 83 PHE A 91 -1 N THR A 90 O THR A 97 SHEET 4 C10 CME A 16 VAL A 23 -1 N VAL A 23 O SER A 83 SHEET 5 C10 PHE A 126 ASP A 134 -1 O LYS A 129 N ARG A 20 SHEET 6 C10 PHE B 126 ASP B 134 -1 O PHE B 133 N LYS A 129 SHEET 7 C10 CME B 16 VAL B 23 -1 N ARG B 20 O LYS B 129 SHEET 8 C10 SER B 83 PHE B 91 -1 O SER B 83 N VAL B 23 SHEET 9 C10 ASN B 95 LYS B 99 -1 O LYS B 99 N CME B 88 SHEET 10 C10 GLU B 105 PRO B 109 -1 O PHE B 108 N LEU B 96 LINK C GLU A 15 N CME A 16 1555 1555 1.33 LINK C CME A 16 N LEU A 17 1555 1555 1.33 LINK C CME A 88 N ILE A 89 1555 1555 1.33 LINK C CME A 130 N AVAL A 131 1555 1555 1.33 LINK C CME A 130 N BVAL A 131 1555 1555 1.33 LINK C GLU B 15 N CME B 16 1555 1555 1.33 LINK C CME B 16 N LEU B 17 1555 1555 1.33 LINK C VAL B 87 N CME B 88 1555 1555 1.33 LINK C CME B 88 N ILE B 89 1555 1555 1.32 LINK C CME B 130 N AVAL B 131 1555 1555 1.33 LINK C CME B 130 N BVAL B 131 1555 1555 1.33 LINK C AVAL A 87 N CME A 88 1555 1555 1.33 LINK C BVAL A 87 N CME A 88 1555 1555 1.32 LINK C LYS A 129 N CME A 130 1555 1555 1.33 LINK C LYS B 129 N CME B 130 1555 1555 1.32 SITE 1 AC1 15 SER A 29 VAL A 31 HIS A 44 ASN A 46 SITE 2 AC1 15 ARG A 48 HIS A 52 ASN A 61 GLU A 71 SITE 3 AC1 15 ARG A 73 ASP A 123 GLY A 124 ASP A 125 SITE 4 AC1 15 HOH A 348 HOH A 356 THR B 70 SITE 1 AC2 9 PRO A 101 ASP A 102 HOH A 330 HOH A 367 SITE 2 AC2 9 ASN B 10 LYS B 12 HOH B 339 HOH B 377 SITE 3 AC2 9 HOH B 403 SITE 1 AC3 20 GLN A 72 GLN A 93 ASN A 113 HOH A 362 SITE 2 AC3 20 SER B 29 VAL B 31 HIS B 44 ASN B 46 SITE 3 AC3 20 ARG B 48 HIS B 52 ASN B 61 GLU B 71 SITE 4 AC3 20 ARG B 73 ASP B 123 GLY B 124 ASP B 125 SITE 5 AC3 20 HOH B 307 HOH B 312 HOH B 349 HOH B 350 CRYST1 43.140 58.410 111.170 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.023180 0.000000 0.000000 0.00000 SCALE2 0.000000 0.017120 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008995 0.00000